

PATENT

Customer No. 22,852

Attorney Docket No. 09602.0001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

National Phase Application of International )  
Application No.: PCT/F103/00254: )  
Inventors: **Jukka SALLINEN et al.** ) Group Art Unit: Unassigned  
Application No.: 10/510,020 ) Examiner: Unassigned  
Filed: October 1, 2004 )  
For: USE OF AN ALFA2- )  
ADRENORECEPTOR ANTAGONIST )  
FOR CNS-RELATED DISEASES )

MAIL STOP PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached form. This Information Disclosure Statement is being filed before a first Office Action on the merits for this application.

Copies of all listed documents are enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form and returning it to Applicants' undersigned representative.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: April 13, 2005

By:   
Steven J. Scott  
Reg. No. 43,911

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/510,020
Filing Date	October 1, 2004
First Named Inventor	Jukka SALLINEN
Art Unit	
Examiner Name	
Attorney Docket Number	09602.0001

## U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		Neal R. Swerdlow et al., "Assessing the Validity of an Animal Model of Deficient Sensorimotor Gating in Schizophrenic Patients," Arch Gen Psychiatry, Vol. 51, pp. 139-154, 1994	
		David L. Braff et al., "Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies," Psychopharmacology, Vol. 156, pp. 234-258, 2001	
		S. Ludewig et al., "Prepulse Inhibition Deficits in Patients with Panic Disorder," Depression and Anxiety, Vol. 15, pp. 55-60, 2002	
		Ewen MacDonald et al., "Gene targeting - homing in on $\alpha_2$ -adrenoceptor-subtype function," Trends in Pharmacological Sciences, Vol. 18, pp. 211-219, 1997	
		M. Scheinin et al., "Evaluation of the $\alpha_{2C}$ -adrenoceptor as a neuropsychiatric drug target, Studies in transgenic mouse models," Life Sciences, Vol. 68, pp. 2277-2285, 2001	
		Mark A. Geyer et al., "Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review," Psychopharmacology, Vol. 156, pp. 117-154, 2001	
		Jukka Sallinen et al., "Adrenergic $\alpha_{2C}$ -Receptors Modulate the Acoustic Startle Reflex, Prepulse Inhibition, and Aggression in Mice," The Journal of Neuroscience, Vol. 18, pp. 3035-3042, 1998	
		Antti Haapalinna et al., "Evaluation of the effects of a specific $\alpha_2$ -adrenoceptor antagonist, atipamezole, on $\alpha_1$ - and $\alpha_2$ -adrenoceptor subtype binding, brain neurochemistry and behavior in comparison with yohimbine," Naunyn-Schmiedeberg's Arch. Pharmacol, Vol. 356, pp. 570-582, 1997	

Examiner  
SignatureDate  
Considered